Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement
Open Access
- 19 May 2022
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 107 (9) , 2255-2260
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014Journal of Clinical Oncology, 2016
- ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotinAnnals of Hematology, 2016
- Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of CrizotinibNew England Journal of Medicine, 2016
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyThe Lancet Oncology, 2014
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group StudyJournal of Clinical Oncology, 2011
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL GroupJournal of Clinical Oncology, 2009
- High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining.1996
- SYSTEMIC CHEMOTHERAPY FOR A PRIMARY GERM-CELL TUMOR OF THE BRAIN - A PHARMACOKINETIC STUDY1981